

**Amendments to the Claims**

Please cancel Claims 21. Please amend Claims 8, 22, 26 and 39. Please add new Claims 42-48. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

- 1-7. (Canceled)
8. (Currently amended) A method of treating an allergic or inflammatory condition associated with ~~IgE-mediated~~ FcεRI-mediated degranulation and/or FcγRIII-mediated degranulation comprising administering to a mammal an effective amount of an antibody agent that binds to CD81 and inhibits FcεRI-mediated degranulation and/or FcγRIII-mediated degranulation ~~IgE-mediated degranulation~~.
9. (Previously presented) The method of Claim 8, wherein the allergic or inflammatory condition is selected from the group consisting of asthma, hay fever and atopic eczema.
- 10-21. (Canceled)
22. (Currently amended) The method of Claim ~~8~~ 21, wherein the ~~anti-CD81~~ antibody that binds to CD81 is a monoclonal antibody.
23. (Previously presented) The method of Claim 8, wherein the allergic or inflammatory condition is selected from the group consisting of autoimmune (Type I) diabetes mellitus, rheumatoid arthritis, ankylosing spondylitis, sarcoidosis, Sjögren's syndrome, multiple sclerosis, inflammatory bowel disease, dermatomyositis, scleroderma, polymyositis, systemic lupus erthematosus, biliary cirrhosis, autoimmune thyroiditis, autoimmune hepatitis, psoriasis, contact sensitivity and atopic dermatitis.

24. (Previously presented) The method of Claim 8 wherein the allergic or inflammatory condition is passive cutaneous anaphylaxis.
25. (Previously presented) The method of Claim 8, wherein the agent does not alter one or more of FcεR1-induced tyrosine phosphorylation, FcεR1-induced intracellular calcium mobilization and leukotriene C<sub>4</sub> (LTC<sub>4</sub>) production.
26. (Currently amended) The method of Claim 8, wherein the ~~IgE-mediated~~ allergic or inflammatory condition associated with FcεRI-mediated degranulation and/or FcγRIII-mediated degranulation is mediated by FcεRI and/or FcγRIII an allergic or inflammatory condition associated with FcεRI-mediated degranulation.
- 27-38. (Canceled)
39. (Currently amended) The method of Claim 8, wherein the ~~IgE-mediated~~ allergic or inflammatory condition associated with FcεRI-mediated degranulation and/or FcγRIII-mediated degranulation is mediated by FcεRI an allergic or inflammatory condition associated with FcγRIII-mediated degranulation.
40. (Previously presented) The method of Claim 8, wherein the allergic or inflammatory condition is asthma.
41. (Previously presented) The method of Claim 8 further comprising administering a physiologically acceptable carrier.
42. (New) The method of Claim 8, wherein the antibody that binds to CD81 is a polyclonal antibody.
43. (New) The method of Claim 8, wherein the antibody that binds to CD81 is mAb 5D1.

44. (New) The method of Claim 8, wherein the antibody that binds to CD81 is mAb 1A12.
45. (New) The method of Claim 8, wherein the allergic or inflammatory condition is an allergic condition.
46. (New) The method of Claim 8, wherein the allergic or inflammatory condition is an anaphylactic reaction.
47. (New) The method of Claim 8, wherein the allergic or inflammatory condition is characterized by mast cell activation.
48. (New) The method of Claim 8, wherein the allergic or inflammatory condition is characterized by basophil activation.